KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Emergent BioSolutions (EBS) Long-Term Debt Issuances (2020 - 2025)

Emergent BioSolutions' Long-Term Debt Issuances history spans 9 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Issuances fell 98.57% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $2.2 million, down 99.0%, while the annual FY2025 figure was $2.2 million, 99.0% down from the prior year.
  • Long-Term Debt Issuances reached $2.2 million in Q4 2025 per EBS's latest filing, down from $154.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $360.0 million in Q4 2022 to a low of $2.2 million in Q4 2025.
  • Average Long-Term Debt Issuances over 4 years is $100.2 million, with a median of $35.0 million recorded in 2023.
  • Peak YoY movement for Long-Term Debt Issuances: soared 670.0% in 2024, then plummeted 98.57% in 2025.
  • A 4-year view of Long-Term Debt Issuances shows it stood at $360.0 million in 2022, then tumbled by 94.44% to $20.0 million in 2023, then skyrocketed by 670.0% to $154.0 million in 2024, then tumbled by 98.57% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Long-Term Debt Issuances are $2.2 million (Q4 2025), $154.0 million (Q4 2024), and $15.0 million (Q2 2024).